---
title: "Windward Bio climbs 5% on $175 million IPO pricing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305707229.md"
description: "Windward Bio rose 4.91% to $29.90 after pricing its IPO to raise $175 million plus a $50 million Sanofi private placement."
datetime: "2026-11-16T19:10:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305707229.md)
  - [en](https://longbridge.com/en/news/305707229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305707229.md)
generator: "portal-rs"
---

# Windward Bio climbs 5% on $175 million IPO pricing

Windward Bio Group (WWB.US) climbed nearly **5%** during regular trading to **$29.90**.

The company priced its Nasdaq initial public offering to raise **$175 million**, excluding the over-allotment option, and simultaneously secured a **$50 million** private placement with Sanofi, bringing total expected proceeds to **$225 million**.

Windward Bio listed on the Nasdaq on Nov. 13, 2026, at an IPO price of **$17** per share. The company focuses on developing ultra-long-acting antibodies for respiratory and dermatological diseases. Its lead candidate, WIN378, has shown positive interim results in asthma and is set to begin a Phase III clinical trial in September 2026.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [WWB.US](https://longbridge.com/en/quote/WWB.US.md)

## Related News & Research

- [Windward Bio prices $175 million Nasdaq IPO](https://longbridge.com/en/news/305634890.md)
- [Windward Bio Raises $50 Million in Private Placement to Sanofi Foreign Participations](https://longbridge.com/en/news/305719353.md)
- [Novo Holdings-backed Windward Bio valued at $1 billion as shares rise in Nasdaq debut](https://longbridge.com/en/news/305492826.md)
- [Innovative Immunology Biotech Windward Bio Lists on Nasdaq](https://longbridge.com/en/news/305550818.md)
- [Baidu (BIDU) Earnings Preview: Profits Seen Falling 46% Despite AI Cloud Boom](https://longbridge.com/en/news/305571383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**